Twist Bioscience Corp (TWST)
NASDAQ:TWST
Want to see TWST full AI Analyst Report?
Top Page
Twist Bioscience
(NASDAQ:TWST)
Select Model
Select Model
Rating:61Neutral
Price Target:
$64.00
▲(7.01% Upside)
Action:ReiteratedDate:05/04/26
The score is held back primarily by weak cash flow and ongoing losses despite improving margins and solid revenue growth. Offsetting this, the technical trend is strong and the latest earnings call provided constructive guidance with a clear path toward adjusted-EBITDA breakeven, while valuation remains constrained by negative earnings.
Positive Factors
Consistent multi-year revenue growth
Sustained top-line growth across multiple years and consecutive quarters indicates durable customer demand and expanding adoption of Twist’s DNA products. A 24% three-year CAGR supports scalable revenue base, helping justify continued investment in capacity and improving operating leverage as volumes rise.
Negative Factors
Persistent negative operating cash flow
Ongoing negative operating and free cash flow means the company continues to burn cash while scaling, requiring external financing or share issuance until operations generate positive cash. This constrains flexibility for opportunistic investment and raises refinancing risk if profitability milestones slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent multi-year revenue growth
Sustained top-line growth across multiple years and consecutive quarters indicates durable customer demand and expanding adoption of Twist’s DNA products. A 24% three-year CAGR supports scalable revenue base, helping justify continued investment in capacity and improving operating leverage as volumes rise.
Read all positive factors
Twist Bioscience (TWST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.70B
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)―
Beta (1Y)2.02
Revenue Growth18.59%
EPS Growth62.54%
CountryUS
Employees923
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.27
Shares Outstanding61,311,703
10 Day Avg. Volume1,242,343
30 Day Avg. Volume1,126,480
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue9.55
Enterprise Value/Gross Profit18.50
Enterprise Value/Ebitda-73.07
Forecast
1Y Price Target
$60.80Price Target Upside1.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.67
Revenue Forecast (FY)$438.63M
Twist Bioscience Business Overview & Revenue Model
Company Description
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic D...
How the Company Makes Money
Twist Bioscience makes money primarily by selling synthetic DNA products and related services to life-science and industrial customers. Key revenue streams include: (1) Sales of synthetic DNA products, such as genes/gene fragments and clonal genes...
Twist Bioscience Earnings Call Summary
Earnings Call Date:May 04, 2026
(Q2-2026)
| Next Earnings Date:Jul 31, 2026
Earnings Call Sentiment Positive
The call presented a predominantly positive operational and commercial story: strong top-line growth (19% YoY), robust outperformance in therapeutics (55% YoY), gross margin above 50%, strategic partnerships (AWS) and an explicit path to adjusted EBITDA breakeven in Q4 FY2026. Offsetting these positives are ongoing adjusted EBITDA losses, higher operating expenses tied to strategic investments, a reduction in cash balances, a pending litigation settlement and certain end-market pressures (academic funding headwinds and some segment declines). Management provided clear remediation steps (cost reductions, targeted automation, acceptance-rate improvements) and raised full-year guidance, indicating confidence in execution.Positive Updates
Consistent Revenue Growth
Total revenue of $110.7M in Q2 FY2026, up 19.3% year-over-year and marking the 13th consecutive quarter of sequential revenue growth.
Negative Updates
Adjusted EBITDA Still Negative
Adjusted EBITDA loss of approximately $13.3M in Q2, although improved ~$1.5M year-over-year; company remains on a path to breakeven but is not yet profitable on an adjusted EBITDA basis.
Read all updates
Q2-2026 Updates
Positive
Negative
Consistent Revenue Growth
Total revenue of $110.7M in Q2 FY2026, up 19.3% year-over-year and marking the 13th consecutive quarter of sequential revenue growth.
Read all positive updates
Company Guidance
Twist guided fiscal 2026 revenue of $442–447 million (growth ~17–19%) and Q3 revenue of $114–115 million (≈19% YoY at the midpoint), said NGS will drive H2 sequential growth and return to ~20% growth by Q4, and reiterated a target of adjusted‑EBITDA breakeven in Q4 FY2026. They expect full‑year gross margin of ~52%+ (Q2 was 51.6%), cited a 75–80% average incremental gross‑margin drop‑through on new revenue, and plan approximately $6 million of sequential OpEx improvement in Q4 from cost actions; Q2 adjusted EBITDA was a loss of ~$13.3 million (an improvement of ~$1.5M YoY). Cash was $171.7 million at quarter end (versus $197.9M at 12/31/25); Q2 used $17.6M in operating cash, spent $7.9M in CapEx and $5.0M on the Invenra license, and recorded $7.2M of litigation settlement costs as part of a ~$17.1M class‑action resolution expected to be largely insurance‑covered.Twist Bioscience Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 391.56M | 376.57M | 312.97M | 245.11M | 203.56M | 132.33M |
| Gross Profit | 202.13M | 191.00M | 133.35M | 89.73M | 84.23M | 51.71M |
| EBITDA | -51.16M | -52.10M | -176.71M | -174.15M | -211.68M | -143.91M |
| Net Income | -76.58M | -77.67M | -208.73M | -204.62M | -217.86M | -152.10M |
Balance Sheet | ||||||
| Total Assets | 638.09M | 641.86M | 614.32M | 776.40M | 961.38M | 702.10M |
| Cash, Cash Equivalents and Short-Term Investments | 197.95M | 232.43M | 276.40M | 336.41M | 504.97M | 477.86M |
| Total Debt | 183.86M | 137.32M | 85.03M | 94.07M | 94.91M | 62.92M |
| Total Liabilities | 181.99M | 168.90M | 141.63M | 152.97M | 171.99M | 121.28M |
| Stockholders Equity | 456.10M | 472.96M | 472.69M | 623.43M | 789.38M | 580.82M |
Cash Flow | ||||||
| Free Cash Flow | -86.72M | -75.63M | -69.17M | -170.25M | -226.24M | -139.31M |
| Operating Cash Flow | -51.01M | -47.63M | -64.09M | -142.47M | -124.39M | -112.24M |
| Investing Cash Flow | -33.16M | -24.76M | -3.07M | 50.61M | -232.93M | 156.16M |
| Financing Cash Flow | 10.89M | 28.54M | 6.89M | 911.00K | 270.53M | 329.18M |
Twist Bioscience Technical Analysis
Positive
59.81
Price Trends
48.60
Positive
42.25
Positive
36.32
Positive
Market Momentum
2.80
Negative
67.77
Neutral
80.60
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TWST, the sentiment is Positive. The current price of 59.81 is above the 20-day moving average (MA) of 49.76, above the 50-day MA of 48.60, and above the 200-day MA of 36.32, indicating a bullish trend. The MACD of 2.80 indicates Negative momentum. The RSI at 67.77 is Neutral, neither overbought nor oversold. The STOCH value of 80.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TWST.
Twist Bioscience Risk Analysis
Twist Bioscience disclosed 61 risk factors in its most recent earnings report. Twist Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Twist Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.11B | 79.03 | -2.61% | ― | 19.17% | -111.99% | |
61 Neutral | $3.70B | -15.88 | -16.58% | ― | 18.59% | 62.54% | |
57 Neutral | $1.23B | -2.80 | -11.82% | ― | 10.95% | -26.52% | |
54 Neutral | $2.22B | -7.70 | -17.11% | ― | 17.18% | 82.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $420.33M | -4.94 | -5.40% | ― | 9.54% | -79.16% | |
48 Neutral | $448.84M | -1.57 | -79.81% | ― | -1.56% | -181.57% |
* Healthcare Sector Average
TWST
Twist Bioscience
60.40
24.47
68.10%
MYGN
Myriad Genetics
4.80
-2.90
-37.66%
NEO
NeoGenomics
9.44
1.60
20.41%
CDNA
CareDx
21.50
6.33
41.73%
FLGT
Fulgent Genetics
14.13
-5.43
-27.76%
GRAL
GRAIL Inc
54.06
19.80
57.79%
Twist Bioscience Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Twist Bioscience Expands Invenra Stake Through Equity Transactions
Positive
Feb 17, 2026
On February 11, 2026, Twist Bioscience Corporation agreed to issue up to 632,328 shares of common stock as part of a series of transactions with Invenra Inc. and two of its investors, including up to 324,558 shares and $5 million in cash to Invenr...
Executive/Board ChangesShareholder Meetings
Twist Bioscience Shareholders Back Directors and Governance Items
Positive
Feb 6, 2026
At its 2026 Annual Meeting of Stockholders, Twist Bioscience Corporation reported that approximately 91.81% of eligible shares were represented in person or by proxy, reflecting strong shareholder engagement. Stockholders elected three Class II di...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.